Your browser doesn't support javascript.
loading
Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia.
Rydholm, Hans; von Corswant, Christian; Denison, Hans; Jensen, Jörgen M; Lehmann, Anders; Ruth, Magnus; Söderlind, Erik; Aurell-Holmberg, Ann.
Affiliation
  • Rydholm H; AstraZeneca Gothenburg, Sweden. Electronic address: hans.rydholm@astrazeneca.com.
  • von Corswant C; AstraZeneca Gothenburg, Sweden.
  • Denison H; AstraZeneca Gothenburg, Sweden.
  • Jensen JM; AstraZeneca Gothenburg, Sweden.
  • Lehmann A; AstraZeneca Gothenburg, Sweden.
  • Ruth M; AstraZeneca Gothenburg, Sweden.
  • Söderlind E; AstraZeneca Gothenburg, Sweden.
  • Aurell-Holmberg A; AstraZeneca Gothenburg, Sweden.
Clin Ther ; 38(4): 946-60, 2016 04.
Article in En | MEDLINE | ID: mdl-26947796
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Paresthesia / Phosphinic Acids / Propylamines / GABA-A Receptor Agonists Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Clin Ther Year: 2016 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Paresthesia / Phosphinic Acids / Propylamines / GABA-A Receptor Agonists Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Clin Ther Year: 2016 Type: Article